Cronos Group, Inc. (CRON)
3.08
-0.09
(-2.84%)
USD |
NASDAQ |
Nov 19, 16:00
3.075
0.00 (0.00%)
After-Hours: 20:00
Cronos Group Enterprise Value : 440.87M for Nov. 19, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 19, 2026 | 440.87M |
| November 18, 2026 | 473.95M |
| November 17, 2026 | 481.30M |
| November 16, 2026 | 510.70M |
| November 13, 2026 | 551.13M |
| November 12, 2026 | 562.16M |
| November 11, 2026 | 576.86M |
| November 10, 2026 | 562.16M |
| November 09, 2026 | 609.93M |
| November 06, 2026 | 635.66M |
| November 05, 2026 | 676.09M |
| November 04, 2026 | 598.91M |
| November 03, 2026 | 551.13M |
| November 02, 2026 | 532.75M |
| October 30, 2026 | 521.73M |
| October 29, 2026 | 543.78M |
| October 28, 2026 | 540.10M |
| October 27, 2026 | 551.13M |
| October 26, 2026 | 525.40M |
| October 23, 2026 | 540.10M |
| October 22, 2026 | 575.02M |
| October 21, 2026 | 554.81M |
| October 20, 2026 | 514.38M |
| October 19, 2026 | 503.35M |
| October 16, 2026 | 488.65M |
| Date | Value |
|---|---|
| October 15, 2026 | 484.97M |
| October 14, 2026 | 470.27M |
| October 13, 2026 | 484.97M |
| October 12, 2026 | 488.65M |
| October 09, 2026 | 496.00M |
| October 08, 2026 | 492.33M |
| October 07, 2026 | 499.68M |
| October 06, 2026 | 516.21M |
| October 05, 2026 | 503.35M |
| October 02, 2026 | 494.16M |
| October 01, 2026 | 488.65M |
| September 30, 2026 | 521.73M |
| September 29, 2026 | 506.10M |
| September 28, 2026 | 517.22M |
| September 25, 2026 | 491.27M |
| September 24, 2026 | 483.86M |
| September 23, 2026 | 513.52M |
| September 22, 2026 | 524.64M |
| September 21, 2026 | 487.57M |
| September 18, 2026 | 494.98M |
| September 17, 2026 | 502.40M |
| September 16, 2026 | 472.74M |
| September 15, 2026 | 439.37M |
| September 14, 2026 | 452.35M |
| September 11, 2026 | 417.13M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Lexaria Bioscience Corp. | 3.495M |
| Target Group, Inc. (Canada) | 11.46M |
| XORTX Therapeutics, Inc. | 1.374M |
| NervGen Pharma Corp. | 150.19M |
| Milestone Pharmaceuticals, Inc. | 48.12M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 17.83M |
| Revenue (Quarterly) | 63.45M |
| Total Expenses (Quarterly) | 49.65M |
| EPS Diluted (Quarterly) | 0.0372 |
| Gross Profit Margin (Quarterly) | 50.31% |
| Profit Margin (Quarterly) | 28.09% |
| Earnings Yield | 5.00% |
| Operating Earnings Yield | 0.86% |
| Normalized Earnings Yield | 5.383 |